|
|
Line 3: |
Line 3: |
| <StructureSection load='6kdi' size='340' side='right'caption='[[6kdi]], [[Resolution|resolution]] 2.70Å' scene=''> | | <StructureSection load='6kdi' size='340' side='right'caption='[[6kdi]], [[Resolution|resolution]] 2.70Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[6kdi]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KDI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6KDI FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6kdi]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KDI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6KDI FirstGlance]. <br> |
- | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=5PY:1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-5-METHYLPYRIMIDIN-2(1H)-ONE'>5PY</scene>, <scene name='pdbligand=64T:5-HYDROXY-THYMIDINE-5-MONOPHOSPHATE'>64T</scene>, <scene name='pdbligand=IAS:BETA-L-ASPARTIC+ACID'>IAS</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.7Å</td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6kdi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6kdi OCA], [http://pdbe.org/6kdi PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6kdi RCSB], [http://www.ebi.ac.uk/pdbsum/6kdi PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6kdi ProSAT]</span></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5PY:1-(2-DEOXY-5-O-PHOSPHONO-BETA-D-ERYTHRO-PENTOFURANOSYL)-5-METHYLPYRIMIDIN-2(1H)-ONE'>5PY</scene>, <scene name='pdbligand=64T:5-HYDROXY-THYMIDINE-5-MONOPHOSPHATE'>64T</scene>, <scene name='pdbligand=IAS:BETA-L-ASPARTIC+ACID'>IAS</scene></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6kdi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6kdi OCA], [https://pdbe.org/6kdi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6kdi RCSB], [https://www.ebi.ac.uk/pdbsum/6kdi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6kdi ProSAT]</span></td></tr> |
| </table> | | </table> |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
Line 16: |
Line 17: |
| </div> | | </div> |
| <div class="pdbe-citations 6kdi" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 6kdi" style="background-color:#fffaf0;"></div> |
| + | |
| + | ==See Also== |
| + | *[[Antibody 3D structures|Antibody 3D structures]] |
| + | *[[3D structures of non-human antibody|3D structures of non-human antibody]] |
| == References == | | == References == |
| <references/> | | <references/> |
Line 22: |
Line 27: |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
| [[Category: Mus musculus]] | | [[Category: Mus musculus]] |
- | [[Category: Hayashida, N]] | + | [[Category: Synthetic construct]] |
- | [[Category: Mizutani, R]] | + | [[Category: Hayashida N]] |
- | [[Category: Noguchi, S]] | + | [[Category: Mizutani R]] |
- | [[Category: Yokoyama, H]] | + | [[Category: Noguchi S]] |
- | [[Category: Fab]]
| + | [[Category: Yokoyama H]] |
- | [[Category: Immune system]]
| + | |
- | [[Category: Immunoglobulin]]
| + | |
- | [[Category: Isoaspartate]]
| + | |
| Structural highlights
Publication Abstract from PubMed
The formation of the isoaspartate (isoAsp) is one of spontaneous degradation processes of proteins, affecting their stability and activity. Here, we report for the first time the crystal structures of an antibody Fab that contains isoAsp in the complementarity-determining region (CDR), along with biochemical studies to detect isoAsp. By comparing the elution profiles of cation-exchange chromatography, it was clarified that the antibody 64M-5 Fab is converted from the normal form to isoAsp form spontaneously and time-dependently under physiological conditions. The isoAsp residue was identified with tryptic peptide mapping, N-terminal sequencing, and the protein isoaspartyl methyltransferase assay. Based on the fluorescence quenching method, the isoAsp form of 64M-5 Fab shows a one order of magnitude lower binding constant for its dinucleotide ligand dT(6-4)T than the normal form. According to the structure of the isoAsp form, the conformation of CDR L1 is changed from the normal form to isoAsp form; the loss of hydrogen bonds involving the Asn28L side-chain, and structural conversion of the beta-turn from type I to type II'. The formation of isoAsp leads to a large displacement of the side chain of His27dL, and decreased electrostatic interactions with the phosphate group of dT(6-4)T. Such structural changes should be responsible for the lower affinity of the isoAsp form for dT(6-4)T than the normal form. These findings may provide insight into neurodegenerative diseases (NDDs) and related diseases caused by misfolded proteins.
Structural and biochemical basis of the formation of isoaspartate in the complementarity-determining region of antibody 64M-5 Fab.,Yokoyama H, Mizutani R, Noguchi S, Hayashida N Sci Rep. 2019 Dec 6;9(1):18494. doi: 10.1038/s41598-019-54918-0. PMID:31811216[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Yokoyama H, Mizutani R, Noguchi S, Hayashida N. Structural and biochemical basis of the formation of isoaspartate in the complementarity-determining region of antibody 64M-5 Fab. Sci Rep. 2019 Dec 6;9(1):18494. doi: 10.1038/s41598-019-54918-0. PMID:31811216 doi:http://dx.doi.org/10.1038/s41598-019-54918-0
|